Related Experiment Video
Updated: Nov 24, 2025
05:02
Modeling Brain Metastasis Via Tail-Vein Injection of Inflammatory Breast Cancer Cells
Published on: February 4, 2021
3.6K
Differences in Genomic Alterations Between Brain Metastases and Primary Tumors
Antonio Dono1,2, Takeshi Takayasu1,2, Yuanqing Yan1
1Vivian L. Smith Department of Neurosurgery, The University of Texas Health Science Center at Houston, McGovern Medical School, Texas.
Neurosurgery
|December 28, 2020
Summary
Genomic alterations differ between brain metastases and primary tumors, impacting prognosis. Identifying these mutations aids in understanding brain metastasis development and improving patient care.
Area of Science:
- Oncology
- Genomics
- Cancer Metastasis
Background:
- Brain metastases (BMs) affect approximately one-third of cancer patients, leading to a poor prognosis.
- The specific mutations driving the development of BMs are not well understood.
- Genomic alterations play a role in the development of BMs.
Purpose of the Study:
- To identify genomic alterations that differ between primary tumors and BMs.
- To understand the genetic landscape of brain metastases.
Main Methods:
- Retrospective analysis of 144 BM patients using next-generation sequencing of 315 genes.
- Comparison of genomic alterations in BMs versus primary tumors from COSMIC and TCGA databases.
- Statistical analysis using chi-square or Fisher's exact test and Kaplan-Meier survival analysis.
Main Results:
- Significant differences in mutation frequencies were observed between primary tumors and BMs.
- Specific genes (e.g., TP53, ATR, APC, ARID1A, ERBB2, CDKN2A/B, ATM) showed increased mutation frequency in BMs across various cancer types.
- Mutations in CREBBP, GPR124, SPTA1 (lung adenocarcinoma) and ERBB2, CDK12, TP53 (breast cancer) were associated with worse prognosis.
Conclusions:
- The study highlights significant genomic differences between primary tumors and BMs.
- Identified targetable alterations and prognostic biomarkers for BM patients.
- Understanding enriched genomic alterations in CNS metastases can improve BM development insights and patient management.
